What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

mRNA Instability: Mechanisms, Regulation, and Biological Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to mRNA Instability

Messenger RNA (mRNA) is the transient intermediary that carries genetic information from DNA to the ribosome, where it directs protein synthesis. Unlike genomic DNA, which is remarkably stable and must be faithfully maintained over the lifetime of a cell, mRNA is inherently unstable. The half-life of a typical mammalian mRNA ranges from minutes to hours, with most transcripts decaying within 2–7 hours. Some short-lived mRNAs, particularly those encoding proto-oncogenes, cytokines, and transcription factors, have half-lives of only 10–30 minutes. In contrast, mRNAs encoding housekeeping proteins such as β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can persist for 10 hours or more.

This instability is not a flaw; it is a fundamental design principle of gene expression. The rapid turnover of mRNA allows cells to adjust protein production quickly in response to developmental cues, environmental stress, or metabolic demands. If mRNAs were as stable as DNA, cells would be unable to mount rapid responses to changing conditions, and aberrant proteins would accumulate unchecked.

The steady-state level of any mRNA—the amount present at any given time—is determined by the balance between its rate of synthesis (transcription and processing) and its rate of degradation. Understanding mRNA instability therefore requires a detailed examination of the decay pathways that target transcripts, the cis-acting elements within the mRNA that mark it for degradation, and the trans-acting factors that execute or regulate these processes.

The Life Cycle of mRNA: From Synthesis to Decay

mRNA Processing and Export

The life of an mRNA begins in the nucleus, where RNA polymerase II transcribes a precursor mRNA (pre-mRNA) from genomic DNA. This primary transcript undergoes extensive co-transcriptional processing before it is competent for export to the cytoplasm. The 5′ end is capped with a 7-methylguanosine cap, which protects the transcript from 5′ exonucleases and is required for efficient translation. The 3′ end is cleaved and polyadenylated, generating a poly(A) tail of approximately 200–250 adenosine residues in mammalian cells. Introns are removed by the spliceosome in a process detailed in mRNA Splicing. These processing events are collectively described in mRNA Processing.

Once fully processed, the mature mRNA is exported through nuclear pore complexes to the cytoplasm, where it engages the translation machinery. The poly(A) tail and the 5′ cap cooperate to stimulate translation initiation: the cap-binding protein eIF4E and the poly(A)-binding protein (PABP) interact through the scaffold protein eIF4G, circularizing the mRNA and promoting ribosome recruitment. This circularized conformation also has profound implications for mRNA stability, as it protects both ends of the transcript from exonucleolytic attack.

Steady-State mRNA Levels

The amount of a given mRNA in the cytoplasm at steady state is the net result of ongoing synthesis and degradation. This relationship is described by the equation:

d[mRNA]/dt = k_synthesis − k_decay × [mRNA]

At steady state, the rate of synthesis equals the rate of decay, and the mRNA level is given by:

[mRNA]_ss = k_synthesis / k_decay

This simple relationship has important implications. A twofold increase in transcription rate doubles the mRNA level, but so does a twofold decrease in the decay rate. Moreover, changes in mRNA stability produce effects that are not instantaneous—after a change in decay rate, it takes several half-lives for the mRNA to reach a new steady state. For a short-lived mRNA with a half-life of 30 minutes, this adjustment occurs within hours. For a stable mRNA with a half-life of 10 hours, the transition takes days. This kinetic distinction explains why unstable mRNAs are preferentially used for genes whose expression must change rapidly.

Why mRNA Must Be Unstable

Rapid Response to Environmental Changes

Cells must constantly adapt to fluctuating conditions—nutrient availability, oxygen tension, hormonal signals, and stress. Transcriptional responses alone are too slow to meet these demands. While transcription and mRNA processing can take minutes to hours, changes in mRNA stability can alter protein production within minutes.

Consider the cellular response to hypoxia. The transcription factor HIF1α is constitutively transcribed, but its mRNA is degraded rapidly under normoxic conditions. When oxygen levels drop, HIF1α mRNA is stabilized, allowing rapid accumulation of the protein and activation of genes involved in anaerobic metabolism and angiogenesis. Similarly, many immediate-early genes, such as c-FOS and c-MYC, encode transcription factors whose mRNAs have half-lives of less than 30 minutes. Their rapid decay ensures that the transcription factors are present only transiently, preventing prolonged or inappropriate gene activation.

The inflammatory response provides another example. Tumor necrosis factor alpha (TNF-α) and other cytokines are encoded by mRNAs containing AU-rich elements that target them for rapid degradation. Upon immune stimulation, these mRNAs are stabilized, allowing a burst of cytokine production. Once the stimulus subsides, the mRNAs are again degraded, returning cytokine levels to baseline. This tight regulation prevents chronic inflammation and tissue damage.

Quality Control and Error Correction

mRNA instability also serves as a quality control mechanism. Transcription and processing are error-prone processes. Even with proofreading, RNA polymerase II introduces errors at a rate of approximately 10⁻⁴ to 10⁻⁵ per nucleotide. Additionally, splicing errors, incomplete processing, or premature translation termination can generate aberrant mRNAs.

Several surveillance pathways detect and degrade defective transcripts. Nonsense-mediated decay (NMD) recognizes mRNAs containing premature termination codons and targets them for degradation, preventing the production of truncated, potentially dominant-negative proteins. Nonstop decay degrades mRNAs lacking a stop codon, while no-go decay targets mRNAs on which ribosomes have stalled. These pathways collectively ensure that only functional, properly processed mRNAs accumulate to significant levels.

The instability of normal mRNAs also prevents the accumulation of proteins that are no longer needed. If an mRNA were perfectly stable, its protein product would continue to be synthesized long after the gene had been transcriptionally silenced, potentially causing developmental or metabolic abnormalities.

Mechanisms of mRNA Decay

The degradation of mRNA in eukaryotic cells occurs primarily through two major pathways: deadenylation-dependent decay and deadenylation-independent decay. Both converge on the removal of protective structures at the mRNA termini, followed by exonucleolytic digestion.

Deadenylation-Dependent Decay

The most common route of mRNA decay begins with the shortening of the poly(A) tail. This process, called deadenylation, is catalyzed by two major deadenylase complexes: the CCR4-NOT complex and the PAN2-PAN3 complex. The CCR4-NOT complex is the major deadenylase in most cells and contains two catalytic subunits, CCR4 (also known as CNOT6) and CAF1 (also known as CNOT7/8). The PAN2-PAN3 complex appears to initiate deadenylation, shortening the poly(A) tail to approximately 110 nucleotides, after which CCR4-NOT completes the process.

Deadenylation proceeds in a 3′ to 5′ direction, removing adenosine residues one at a time. The rate of deadenylation varies among mRNAs and is influenced by cis-acting elements and RNA-binding proteins. When the poly(A) tail is shortened to approximately 15–20 nucleotides, the mRNA becomes incompetent for translation and is committed to degradation. The loss of PABP from the shortened tail exposes the mRNA to further decay.

Decapping and 5′ to 3′ Decay

Following deadenylation, the 5′ cap can be removed by the decapping enzyme DCP2, which requires the co-activator DCP1 and additional accessory proteins such as EDC3, EDC4, and the LSM1-7 complex. Decapping exposes the 5′ end to the major 5′ to 3′ exonuclease, XRN1, which processively degrades the mRNA from the 5′ end.

The 5′ to 3′ decay pathway is the predominant route of mRNA degradation in yeast and is also highly active in mammalian cells. Decapping and 5′ to 3′ decay often occur in cytoplasmic foci called processing bodies (P-bodies), which are enriched in DCP2, XRN1, and other decay factors. P-bodies are dynamic structures; they form when decay intermediates accumulate and disassemble when decay is complete. Importantly, P-bodies are not required for mRNA decay—decay can occur in the cytoplasm—but they may serve to concentrate decay factors and sequester translationally repressed mRNAs.

3′ to 5′ Decay and the Exosome

An alternative decay route degrades mRNA from the 3′ end. After deadenylation, the exosome—a multi-subunit complex with 3′ to 5′ exoribonuclease activity—can degrade the mRNA. The exosome contains a core of nine subunits, of which six have RNase PH-like domains, and is associated with the catalytic subunit DIS3 (also known as RRP44) in the cytoplasm. The exosome requires the cooperation of the SKI complex, which unwinds secondary structures and facilitates processive degradation.

The 3′ to 5′ pathway is generally less prominent than the 5′ to 3′ pathway in yeast but plays a more significant role in mammalian cells, particularly for mRNAs with strong secondary structures that impede 5′ to 3′ decay. The exosome also degrades nuclear RNAs, including aberrant pre-mRNAs and noncoding RNAs, as part of nuclear quality control.

The major mRNA decay pathways are summarized in the following table:

Pathway	Initiating Event	Key Enzymes	Direction of Decay	Primary Location
Deadenylation-dependent decay	Poly(A) tail shortening	CCR4-NOT, PAN2-PAN3	3′ to 5′ (deadenylation)	Cytoplasm
5′ to 3′ decay	Decapping after deadenylation	DCP2, XRN1	5′ to 3′	P-bodies, cytoplasm
3′ to 5′ decay	Deadenylation, then exosome action	Exosome, DIS3, SKI complex	3′ to 5′	Cytoplasm, nucleus
Endonucleolytic decay	Internal cleavage	RNase L, SMG6, other endonucleases	Internal cut, then exonucleolytic	Cytoplasm

Endonucleolytic cleavage represents a less common but important decay mechanism. In this pathway, an endonuclease cleaves the mRNA internally, generating two fragments that are then degraded by exonucleases. RNase L, activated by 2′-5′ oligoadenylates during the interferon response, cleaves viral and cellular mRNAs. SMG6, a component of the NMD pathway, cleaves mRNAs near premature termination codons. Endonucleolytic cleavage provides a rapid, one-step mechanism for mRNA destruction that does not require prior deadenylation.

Cis-Acting Elements and Trans-Acting Factors in mRNA Stability

The stability of individual mRNAs is not uniform; it is determined by specific sequences and structures within the mRNA (cis-acting elements) and the proteins or RNAs that bind them (trans-acting factors).

AU-Rich Elements (AREs)

AU-rich elements are the best-characterized cis-acting determinants of mRNA instability. These elements are typically located in the 3′ untranslated region (UTR) and contain multiple copies of the pentamer AUUUA, often within a U-rich context. AREs are classified into three groups based on their sequence features:

Class I AREs: Contain one to three scattered copies of AUUUA within a U-rich region (e.g., c-MYC, c-FOS).
Class II AREs: Contain multiple overlapping copies of AUUUA (e.g., TNF-α, GM-CSF).
Class III AREs: Lack the canonical AUUUA pentamer but are U-rich (e.g., c-JUN).

AREs promote mRNA decay by recruiting ARE-binding proteins (ARE-BPs) that stimulate deadenylation, decapping, or endonucleolytic cleavage. The best-studied ARE-BP is tristetraprolin (TTP), which binds Class II AREs and recruits the CCR4-NOT deadenylase complex, promoting rapid mRNA degradation. TTP is itself regulated: its activity is inhibited by phosphorylation by p38 MAPK and MK2, which promotes binding to 14-3-3 proteins and prevents TTP from accessing its mRNA targets. This regulatory circuit allows inflammatory mRNAs to be stabilized rapidly upon cellular activation.

RNA-Binding Proteins

In addition to ARE-BPs, numerous other RNA-binding proteins regulate mRNA stability. The Hu family proteins (HuR, HuB, HuC, HuD) are stabilizing factors that bind AREs and protect mRNAs from degradation. HuR is ubiquitously expressed and, upon stress or mitogenic stimulation, translocates from the nucleus to the cytoplasm, where it stabilizes target mRNAs encoding stress-response and proliferation-related proteins.

Other RNA-binding proteins act more broadly. The poly(C)-binding proteins (PCBP1-4) stabilize specific mRNAs by binding C-rich elements. The insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) stabilize mRNAs involved in cell proliferation and are overexpressed in many cancers. Conversely, proteins such as KSRP (KH-type splicing regulatory protein) promote decay by recruiting the exosome and the decapping complex.

The specificity of these interactions is remarkable. A single RNA-binding protein can regulate dozens or hundreds of target mRNAs, and a single mRNA can be bound by multiple proteins with opposing effects. The net stability of an mRNA is therefore determined by the balance of stabilizing and destabilizing factors in a given cellular context.

MicroRNA-Mediated mRNA Decay

MicroRNAs (miRNAs) are ~22-nucleotide noncoding RNAs that regulate gene expression post-transcriptionally. miRNAs are incorporated into the RNA-induced silencing complex (RISC), where they guide Argonaute proteins (AGO1-4 in mammals) to complementary sequences in target mRNAs, typically in the 3′ UTR. Perfect complementarity leads to endonucleolytic cleavage by AGO2, but in mammals, most miRNA-mRNA interactions involve imperfect base pairing, leading to translational repression and mRNA destabilization.

miRNA-mediated mRNA decay occurs primarily through the recruitment of the CCR4-NOT complex, which deadenylates the target mRNA, followed by decapping and 5′ to 3′ decay. The GW182 family proteins (TNRC6A-C in mammals) are essential scaffolds that link AGO proteins to the deadenylase complex. This pathway is responsible for the regulation of a large fraction of the transcriptome; it is estimated that more than 60% of human protein-coding genes are conserved targets of miRNAs.

The importance of miRNA-mediated decay is underscored by the observation that individual miRNAs can regulate hundreds of target mRNAs, and that miRNA dysregulation is associated with numerous diseases, including cancer, cardiovascular disease, and neurological disorders.

Experimental Methods to Study mRNA Instability

Transcriptional Shut-Off Assays

The classic approach to measuring mRNA stability is the transcriptional shut-off assay. In this method, new transcription is inhibited, and the decay of the existing mRNA pool is monitored over time. The most commonly used inhibitor is actinomycin D, which intercalates into DNA and blocks RNA polymerase I, II, and III. Actinomycin D is typically used at concentrations of 5–10 µg/mL for mammalian cells. The mRNA level is then measured at multiple time points (e.g., 0, 1, 2, 4, 8 hours) by northern blotting, quantitative RT-PCR, or RNA sequencing.

The half-life is calculated from the decay curve using the equation:

t₁/₂ = ln(2) / k_decay

where k_decay is the first-order decay constant obtained from a semi-logarithmic plot of mRNA remaining versus time.

A major limitation of actinomycin D is its global toxicity; prolonged treatment induces cellular stress and apoptosis, which can alter mRNA stability indirectly. The transcriptional inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is sometimes used as an alternative, as it specifically inhibits RNA polymerase II. However, DRB also has off-target effects.

RNA Half-Life Measurement

More sophisticated approaches use metabolic labeling to measure mRNA decay without globally inhibiting transcription. In these methods, cells are incubated with a nucleotide analog such as 4-thiouridine (4sU) or 5-ethynyl-uridine (EU), which is incorporated into newly synthesized RNA. After a labeling period, the analog is removed, and the decay of labeled RNA is monitored over time. Newly transcribed RNA is distinguished from pre-existing RNA by biochemical purification (e.g., biotinylation of 4sU-containing RNA followed by streptavidin pull-down) or by click chemistry for EU-labeled RNA.

These methods allow the measurement of mRNA decay rates transcriptome-wide and can distinguish between changes in transcription and changes in decay. However, they require careful optimization of labeling times and concentrations to avoid perturbing cellular physiology.

Reporter Systems

Reporter gene assays provide a convenient way to study mRNA stability in a controlled context. In these systems, a reporter gene such as firefly luciferase, green fluorescent protein (GFP), or β-galactosidase is placed under the control of a regulatable promoter, and the sequence of interest (e.g., an ARE or a specific 3′ UTR) is inserted into the reporter mRNA. The decay of the reporter mRNA is then measured after transcriptional shut-off.

The use of destabilized reporters, such as those containing a PEST sequence that targets the protein for rapid degradation, allows the measurement of mRNA decay without the confounding effects of protein accumulation. Dual-luciferase assays, in which a test reporter and a normalization control are co-transfected, provide a quantitative readout of mRNA stability.

Reporter systems are particularly useful for dissecting the contributions of specific cis-acting elements and for screening for trans-acting factors that regulate mRNA stability. However, results obtained with reporter constructs must be validated in the context of the endogenous gene, as the local chromatin environment and the presence of additional regulatory elements can influence mRNA stability.

mRNA Instability in Disease and Biotechnology

Disease Implications

Dysregulation of mRNA stability contributes to the pathogenesis of numerous human diseases. In cancer, the stabilization of mRNAs encoding proto-oncogenes, growth factors, and angiogenic factors can drive uncontrolled cell proliferation. For example, the mRNA encoding cyclin D1 (CCND1) is stabilized in many cancers due to increased expression of HuR or decreased expression of TTP, leading to elevated cyclin D1 protein levels and accelerated cell cycle progression. Similarly, the stabilization of VEGF mRNA promotes tumor angiogenesis.

Chronic inflammatory diseases are associated with the stabilization of cytokine mRNAs. In rheumatoid arthritis, the TNF-α mRNA is stabilized in synovial macrophages, leading to persistent TNF-α production and chronic inflammation. The anti-inflammatory effects of corticosteroids are mediated in part by the induction of TTP, which destabilizes TNF-α and other cytokine mRNAs.

Conversely, excessive mRNA instability can also cause disease. Loss-of-function mutations in TTP in mice result in a severe inflammatory syndrome characterized by arthritis, dermatitis, and myeloid hyperplasia, due to the accumulation of TNF-α and other inflammatory mediators. In humans, polymorphisms in ARE-containing genes that alter mRNA stability have been associated with susceptibility to inflammatory and autoimmune diseases.

mRNA Vaccines and Therapeutics

The instability of mRNA is a central challenge for mRNA-based therapeutics. For an mRNA vaccine to be effective, the mRNA must survive long enough in the cytoplasm to be translated into sufficient antigen to elicit an immune response. However, the inherent instability of mRNA limits its expression duration.

Several strategies are used to increase the stability of therapeutic mRNAs. The incorporation of modified nucleosides, such as N1-methylpseudouridine, reduces innate immune activation and increases mRNA stability by evading recognition by pattern recognition receptors. The optimization of codon usage and the inclusion of stable 5′ and 3′ UTRs, such as those derived from α- and β-globin mRNAs, also enhance mRNA stability and translation. The poly(A) tail length is optimized (typically 100–150 nucleotides) to balance stability and translational efficiency.

The Property of mRNA and its Translatability of mRNA Sequences are critical considerations in the design of therapeutic mRNAs. The Translatability of mRNA in Vitro is particularly relevant for the production of mRNA vaccines, where in vitro transcription is used to synthesize the mRNA. Understanding the Difference Between mRNA and Non mRNA Vaccine is essential for appreciating the unique advantages and challenges of mRNA-based approaches.

The success of mRNA vaccines against SARS-CoV-2 demonstrated the clinical utility of this platform. The vaccines achieve sufficient antigen expression despite mRNA instability by delivering the mRNA in lipid nanoparticles, which protect the mRNA from extracellular nucleases and facilitate cellular uptake. Once inside the cell, the mRNA is translated for several days before being degraded, providing ample antigen to stimulate a robust immune response.

Common Pitfalls and Misconceptions

Students frequently encounter several conceptual difficulties when studying mRNA instability. Understanding these pitfalls is essential for mastering the material.

Confusing mRNA instability with DNA instability. Genomic DNA is highly stable; it is replicated once per cell cycle and is protected by DNA repair mechanisms. mRNA, in contrast, is continuously synthesized and degraded. The instability of mRNA is a regulated, functional property, not a sign of damage or error.

Equating mRNA half-life with protein half-life. The half-life of an mRNA refers to the time required for half of the mRNA molecules to be degraded. The half-life of the encoded protein is a separate parameter, determined by protein degradation pathways such as the ubiquitin-proteasome system. A short-lived mRNA can encode a long-lived protein, and vice versa.

Assuming that all mRNAs in a cell have the same stability. mRNA half-lives vary over at least two orders of magnitude, from minutes to days. This variation is determined by cis-acting elements and trans-acting factors, and it is dynamically regulated in response to cellular signals.

Confusing decay rate with steady-state level. A change in mRNA stability does not immediately change the mRNA level; the new steady state is approached exponentially over several half-lives. Conversely, a change in steady-state mRNA level does not necessarily indicate a change in stability; it could reflect a change in transcription.

Thinking that deadenylation is the only decay pathway. While deadenylation is the most common initiating step, some mRNAs are degraded by deadenylation-independent pathways, including decapping without prior deadenylation and endonucleolytic cleavage.

Believing that P-bodies are required for mRNA decay. P-bodies are sites where decay factors and translationally repressed mRNAs concentrate, but mRNA decay can occur throughout the cytoplasm. P-bodies are not essential for decay; they are a consequence of the accumulation of decay intermediates.

Assuming that miRNA-mediated regulation always leads to mRNA degradation. In mammals, miRNAs typically cause both translational repression and mRNA destabilization. The relative contribution of each mechanism varies among targets and cellular contexts. Some miRNA targets are primarily translationally repressed with minimal mRNA decay.

Frequently Asked Questions

Is mRNA unstable?

Yes, mRNA is inherently unstable. The half-life of most mammalian mRNAs is between 2 and 7 hours, although some transcripts are degraded within minutes and others persist for more than 24 hours. This instability is a regulated property that allows cells to rapidly adjust gene expression in response to changing conditions.

Why is mRNA unstable?

mRNA instability serves several essential functions. It allows cells to rapidly change protein production in response to environmental signals, prevents the accumulation of aberrant or misfolded proteins, and provides a mechanism for quality control. If mRNAs were stable, cells would be unable to mount rapid responses to stimuli, and the expression of genes that should be transient would persist inappropriately.

What determines the half-life of an mRNA?

The half-life of an mRNA is determined by its sequence and structure, particularly in the 5′ and 3′ untranslated regions. Cis-acting elements such as AU-rich elements, stem-loop structures, and miRNA binding sites recruit trans-acting factors that either stabilize or destabilize the mRNA. The activity of these factors is regulated by cellular signaling pathways, so mRNA stability is dynamically controlled.

How is mRNA stability measured?

mRNA stability is commonly measured by transcriptional shut-off assays, in which new transcription is inhibited with actinomycin D or DRB, and the decay of the existing mRNA is monitored over time. More sophisticated methods use metabolic labeling with nucleotide analogs such as 4-thiouridine to distinguish newly transcribed from pre-existing mRNA. Reporter gene assays are used to study the effects of specific sequences on mRNA stability.

What is the difference between mRNA stability and DNA stability?

Genomic DNA is extremely stable; it is replicated once per cell cycle and is protected by elaborate repair mechanisms. mRNA, in contrast, is continuously synthesized and degraded, with half-lives ranging from minutes to hours. The instability of mRNA is a functional property that enables rapid and reversible changes in gene expression, whereas the stability of DNA ensures the faithful transmission of genetic information.

Can mRNA instability be beneficial?

Yes, mRNA instability is beneficial in many contexts. It allows cells to rapidly shut off gene expression when a stimulus is removed, prevents the accumulation of potentially harmful proteins, and enables the precise temporal control of developmental processes. The instability of mRNAs encoding transcription factors and signaling molecules is particularly important for preventing inappropriate or prolonged cellular responses.

What happens if mRNA is too stable?

If mRNA is too stable, the encoded protein continues to be produced long after transcription has ceased. This can lead to the accumulation of proteins that should be transient, causing developmental abnormalities, uncontrolled cell proliferation, or chronic inflammation. For example, the stabilization of cytokine mRNAs contributes to chronic inflammatory diseases, and the stabilization of proto-oncogene mRNAs promotes cancer.

Key Takeaways

mRNA instability is a fundamental property of gene expression, with half-lives ranging from minutes to hours, and it is determined by the balance between synthesis and degradation.
The major decay pathways are deadenylation-dependent decay, decapping followed by 5′ to 3′ exonucleolytic decay, and 3′ to 5′ decay by the exosome.
Cis-acting elements such as AU-rich elements and miRNA binding sites, together with trans-acting RNA-binding proteins, determine the stability of individual mRNAs.
mRNA instability enables rapid responses to environmental changes and provides quality control against aberrant transcripts.
Dysregulation of mRNA stability contributes to cancer, inflammatory diseases, and other pathologies.
The instability of mRNA is a major consideration in the design of mRNA vaccines and therapeutics, which use modified nucleosides and optimized UTRs to enhance stability.
Understanding the distinction between mRNA stability and DNA stability, and between decay rate and steady-state level, is essential for interpreting gene expression data.